Boston Immune Technologies & Therapeutics
Winchester
About Boston Immune Technologies & Therapeutics
BITT has developed a platform for targeting the tumor necrosis factor receptor 2 (TNFR2) oncogene and the potent population of TNFR2 Tregs in the tumor microenvironment.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 1 – 10
- Estimated revenue: $1K – $10K
- Total funding: $14.0M
- Funding stage: Early Stage Venture
- Last round: Grant (Aug 2024)
- Website: bostonimmunetech.com
Industries & Categories
Biotechnology, Therapeutics
Canonical: https://fsome.com/organization/boston-immune-technologies-therapeutics-66383 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.